Nektar Therapeutics (NKTR) concluded trading on Wednesday at a closing price of $0.73, with 4.85 million shares of worth about $3.54 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.14% during that period and on February 12, 2025 the price saw a gain of about 10.22%. Currently the company’s common shares owned by public are about 184.46M shares, out of which, 177.74M shares are available for trading.
Stock saw a price change of -3.82% in past 5 days and over the past one month there was a price change of -23.96%. Year-to-date (YTD), NKTR shares are showing a performance of -21.40% which increased to 2.96% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.63 but also hit the highest price of $1.93 during that period. The average intraday trading volume for Nektar Therapeutics shares is 1.94 million. The stock is currently trading -10.53% below its 20-day simple moving average (SMA20), while that difference is down -21.73% for SMA50 and it goes to -40.27% lower than SMA200.
Nektar Therapeutics (NASDAQ: NKTR) currently have 184.46M outstanding shares and institutions hold larger chunk of about 74.01% of that.
The stock has a current market capitalization of $134.84M and its 3Y-monthly beta is at 0.68. It has posted earnings per share of -$0.84 in the same period. It has Quick Ratio of 4.24 while making debt-to-equity ratio of 4.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NKTR, volatility over the week remained 11.19% while standing at 8.24% over the month.
Stock’s fiscal year EPS is expected to rise by 50.60% while it is estimated to decrease by -6.97% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on January 08, 2025 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by H.C. Wainwright stated Nektar Therapeutics (NKTR) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $6.50 for the stock. On November 04, 2024, Piper Sandler Initiated their recommendations, while on September 30, 2024, BTIG Research Resumed their ratings for the stock with a price target of $4. Stock get a Buy rating from Rodman & Renshaw on June 28, 2024.
